• PDF / 170,215 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 58 Downloads / 169 Views

DOWNLOAD

REPORT

---

1 S

COVID-2019 pneumonia: case report A 50-year-old woman developed COVID-2019 pneumonia during treatment with clozapine and quetiapine for schizophrenia. The woman, who had schizophrenia, was receiving treatment with clozapine 300mg daily and quetiapine 100mg daily [routes not stated]. Her schizophrenia was stable on this treatment. She had a medical history of obesity, diabetes and active cigarette use. In April 2020, she was admitted to an emergency department due to a 2-week history of cough, worsening shortness of breath and fever. It was reported that her last clozapine level was found to be 296 ng/mL on October 2019 while taking clozapine 175mg daily with a normal monthly absolute neutrophil count. After admission, it was noted that she was febrile, in respiratory distress and with oxygen saturation of 92%. A chest x-ray revealed bilateral opacities. Further laboratory workup showed CRP 330.4 mg/L, lymphopenia 900 /µL and haemoglobin A1c 8%. Her COVID-2019 test was found to be positive. Based on presenting symptoms and findings, she was diagnosed with COVID-2019 pneumonia [durations of treatments to reaction onset not stated]. The woman’s clozapine and quetiapine treatments were discontinued. Due to the hypoxic respiratory failure, she was intubated and was transferred to an ICU. Later, she developed hypotension, worsening hypoxemia and vaginal bleeding. On 6th day of admission, she showed evidence of pulmonary embolus. Therefore, she was started on an unspecified tissue plasminogen activator, but no improvement was seen and she died. It was considered that, her clozapine treatment along with quetiapine increased the risk of the pneumonia. Llesuy JR, et al. Death From COVID-19 in a Patient Receiving Clozapine: Factors Involved and Prevention Strategies to Consider. Primary Care Companion for CNS 803501634 Disorders 22: 1-2, No. 4, 23 Jul 2020. Available from: URL: http://doi.org/10.4088/PCC.20l02699

0114-9954/20/1822-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 19 Sep 2020 No. 1822